CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Astellas Pharma Inc. v. Sandoz Inc.

1:16-cv-00952

Overview

Case Number 1:16-cv-00952
Filing Date 2016-10-14
Status Terminated
Termination Date 2020-10-05
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Plaintiff

Astellas Pharma Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Counter Claimant

Sandoz Inc. Operating Company

Represented By

5 Attorneys Listed

William A. Rakoczy

Email: wrakoczy@rmmslegal.com

Deanne M. Mazzochi

Email: dmazzochi@rmmslegal.com

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Avenue, Suite 200, Wilmington, DE 19801

Anuj K. Wadhwa

Email: awadhwa@rmmslegal.com

Conly S. Wythers

Email: cwythers@rmmslegal.com

Counter Defendant

Astellas Pharma Global Development, Inc. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Astellas Ireland Co., Ltd. Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 4 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 8 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (4): πŸ‡―πŸ‡΅ Japan πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (8 found):
U.S. Courts: 8
U.S. District Court 2023-06-09
1:23-cv-00629

Astellas Pharma Inc. v. Evitalin LLC

Asserted Patent
Status: DED
U.S. District Court 2016-10-21
1:16-cv-00976

Astellas Pharma Inc. v. Apotex Inc.

Asserted Patent
Status: DED
U.S. District Court 2016-10-17
1:16-cv-00954

Astellas Pharma Inc. v. Sawai Pharmaceutical Co., Ltd.

Asserted Patent
Status: DED
U.S. District Court 2016-10-13
1:16-cv-00942

Astellas Pharma Inc. v. Aurobindo Pharma Ltd.

Asserted Patent
Status: DED
U.S. District Court 2016-10-12
1:16-cv-00930

Astellas Pharma Inc. v. Windlas Healthcare Pvt. Ltd.

Asserted Patent
Status: DED
U.S. District Court 2016-10-11
1:16-cv-00924

Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA), Inc.

Asserted Patent
Status: DED
U.S. District Court 2016-10-07
1:16-cv-00908

Astellas Pharma Inc. v. Lupin Ltd.

Asserted Patent
Status: DED
U.S. District Court 2016-10-06
1:16-cv-00905

Astellas Pharma Inc. v. Actavis Elizabeth LLC

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7342117
Ξ±-form or Ξ²-form crystal of acetanilide derivative
Filed: 2002-10-20
Issued: 2008-03-11
Expired (Term Ended) +371d PTA
Expires: 2023-10-26
US7982049
Ξ±-form or Ξ²-form crystal of acetanilide derivative
Filed: 2008-01-14
Issued: 2011-07-19
Expired (Term Ended)
Expires: 2026-04-07
US8835474
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Filed: 2011-05-27
Issued: 2014-09-16
Active (4.5 yrs remaining)
Expires: 2031-05-27
USRE44872
Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Filed: 2003-11-04
Issued: 2014-04-29
Expired (Term Ended) +44d PTA
Expires: 2023-12-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+371 days) / Cellect Scrutiny β€” Over 371 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

3

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 1 Claim Construction / Markman Filing 2

Key Dispositive Motions & Rulings

Claim Construction / Markman Filing Referred to Magistrate
ORAL ORDER - Pursuant to the filing of this case, the Court issues the following order: This case shall be immediately referred to Magistrate Judge Christopher ...
Entry #22 • 2017-08-10 Document →
Claim Construction / Markman Filing Pending
SO ORDERED, re (22 in 1:16-cv-00954-SLR, 25 in 1:16-cv-00908-SLR, 25 in 1:16-cv-00905-SLR, 21 in 1:16-cv-00976-SLR, 24 in 1:16-cv-00924-SLR, 26 in 1:16-cv-00942...
Entry #β€” • 2017-03-16
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for defendant to file any supplemental counterclaims and for plaintiffs to answer, move, or otherwise respond to any counterclaims to...
Entry #16 • 2017-01-09 Document →

Docket Entries

(46 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGMENT filed against Sandoz Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2013226.) - filed by Astellas Pharma Inc., Astellas Ireland Co., Ltd., Astellas Pharma Global Development, Inc.. (Attachments: # 1 Exhibit A-D, # 2 Civil Cover Sheet)(cna) (Entered: 10/14/2016)

Entry #1 • 2016-10-14
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cna) (Entered: 10/14/2016)

Entry #2 • 2016-10-14
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/10/2016. Date of Expiration of Patent: 11/4/2023.Thirty Month Stay Deadline: 12/28/2019. (cna) (Entered: 10/14/2016)

Entry #3 • 2016-10-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,342,117 B2; 7,982,049 B2; 8,835,474 B2; RE44,872 E. (cna) (Entered: 10/14/2016)

Entry #4 • 2016-10-14
1

Disclosure Statement pursuant to Rule 7.1: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Astellas Pharma Inc.. Corporate Parent Astellas B.V. for Astellas Ireland Co., Corporate Parent Astellas US Holding, Inc. for Astellas Pharma Global Development, Inc. filed by Astellas Pharma Inc., Astellas Ireland Co., LTD., and Astellas Pharma Global Development,Inc.(cna) (Entered: 10/14/2016)

Entry #5 • 2016-10-14
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc